Epigenetics Diagnostics Market By Product, By Technology, By Application, By End User, Distribution Channel and By Region - Market Trends, Analysis, and Forecast till 2030

Epigenetics Diagnostics Market accounted for USD 4265.23 Million in 2020 and is estimated to be USD 12686.6 Million by 2030 and is anticipated to register a CAGR of 11.5%.

The study of genetics, cellular and physical characteristic changes, and developmental biology that are induced by the external environment is known as epigenetics diagnosis. This, in turn, has an effect on genes and the ability of cells to read genes without being influenced by genotype. The underlying DNA and RNA sequences remain unaltered, and epigenetic modifications result in changes in the phenotype of the organism rather than the genotype. Because epigenetic modifications are dynamic and change with the environment, they are critical for development. Epigenetics affects the genetic manifestations of organisms, making it the most important topic in molecular biology and developmental genetics. The National Center Institute, the National Institute of Health, and the International Human Epigenome Consortium are all sponsoring and supporting epigenetics research and development. Epigenetics is also utilised to treat a number of chronic disorders, including cancer, metabolic diseases, and autoimmune diseases.

Funds in Research and Development Projects will drive the growth of the Market

These organizations are expected to fund research and development projects in order to better understand epigenetic alterations at the molecular level and find therapeutic treatments. Furthermore, the NCI's Division of Cancer's Epidemiology and Genomics Research Program (EGRP) funds research projects based on innovative epigenetic research, which is a driving force in the industry. For instance, According to the National Institutes of Health, the number of cancer fatalities in the United States is expected to be 171.2 per 100,000 men and women per year. The high prevalence is due to the high incidence rate, death and survival data, information on cancer symptoms, risk factors, early detection, and early treatment. The International Cancer Genome Consortium (ICGC) is working to characterize the genomics, epigenomic alterations, and transcriptome changes in various tumor types.

Epigenetics players are partnering with one another to improve epigenetics application. This is projected to open up a number of attractive opportunities for the global epigenetics market to expand. Other key factors projected to boost growth in the worldwide epigenetic diagnostics market include rising cases of cancer and other chronic diseases around the world, as well as an increase in the geriatric population. Furthermore, increased commercial and public investment is supporting enhanced gene, cellular, and protein research, resulting in significant epigenetic reagent advances. Furthermore, epigenetic variables such as chromatin structure, non-coding RNAs, and DNA methylation can be used to influence gene expression. This is pushing epigenetics acceptance in the life sciences and analytical tools markets, resulting in increased demand for epigenetics globally. Finally, rising FDA approval of several epigenetics diagnostics medications and equipment is likely to boost the market forward.

The Global Epigenetics Diagnostics Market is segmented based on product, technology, application, end-user, distribution channel and region.

On the basis of Product, the Global Epigenetics Diagnostics Market is segmented into Reagents, Kits, Instruments & Consumables, and Bioinformatics Tools & Enzymes. Based on Technology, the target market is segmented into DNA Methylation, Histone Methylation, Chromatin Structures, Histone Acetylation, and Large Non-Coding RNA & MicroRNA Modification. Based on Application, the target market is segmented into Oncology, Cardiovascular Diseases, Metabolic Diseases, Immunology, Inflammatory Diseases, and Infectious Diseases & Others. Based on End-User, the target market is segmented into Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) & others. Based on Distribution Channel, the target market is segmented into Direct Tender & Retail Sales.

Regional Insights:                                                

On region the Global Epigenetics Diagnostics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2020, North America surpassed Europe as the most important regional market. The presence of advanced technological facilities, successful initiatives, the constantly growing ageing population, enhanced healthcare facilities, government financing for ongoing epigenetic research activities, attentive research, and precise diagnostic techniques are all major market drivers. Furthermore, the Common Fund-funded projects in the United States are expected to expand epigenetic research activities across a wide variety of disorders, including oncology and non-oncology diseases like cardiovascular, metabolic, and inflammatory diseases. Due to increased disposable income, significant unmet clinical requirements of patients, rising knowledge of early diagnosis, and availability of efficient treatment in emerging nations such as India and China, Asia Pacific is expected to grow at the quickest rate over the projection period. Due to an increase in cancer cases, Asia Pacific is in the spotlight.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Epigenetics Diagnostics Market report based on product, technology, application, end-user, distribution channel and region.

Global Epigenetics Diagnostics Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the epigenetics diagnostic market are Zymo Research Corporation, PerkinElmer Inc., Diagenode, a Hologic company, F. Hoffman-La Roche Ltd, EPICYPHER, Cambridge Epigenetix (CEGX), Promega Corporation, QIAGEN, Pacific Biosciences of California, Inc., Epigenomics AG, Mnemo, Reaction Biology, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Merck KGaA, Illumina, Inc., ACTIVEMOTIF, New England Biolabs, Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Enzo Life Sciences, Inc., Epizyme, Inc., GlaxoSmithKline plc., Eclipse BioInnovations, MDxHealth, Abcam plc., Salarius Pharmaceuticals, Inc., Datar Cancer Genetics, and Bluestar Genomics Inc. among others.

• Zymo Research Corporation
• PerkinElmer Inc.
• Diagenode
• Hologic company
• F. Hoffman-La Roche Ltd
• Cisco Systems
• EPICYPHER
• Cambridge Epigenetix (CEGX)